MR contrast developer Advanced Magnetics and biopharmaceutical firm Cytogen of Princeton, NJ, reported that the Food and Drug Administration's Oncologic Drugs Advisory Committee is scheduled to review the regulatory filing for Combidex, Advanced Magnetics' investigational MRI contrast agent, on March 3, this year.
The companies are jointly preparing for the upcoming meeting, according to Cambridge, MA-based Advanced Magnetics.
By AuntMinnie.com staff writers
February 1, 2005
Related Reading
Advanced Magnetics boosts sales, losses in Q1, January 18, 2005
Advanced Magnetics, Cytogen get FDA nod, October 20, 2004
Advanced Magnetics post Q3 loss, July 19, 2004
Advanced Magnetics taps CFO, July 12, 2004
Advanced Magnetics launches clinical study, June 1, 2004
Copyright © 2005 AuntMinnie.com
